Platinum-resistant relapse, several options
62platinum-resistant HGSOC, ECOG 1several listed options
Narrow the field, or start from the front-runner?
What matters now
Platinum-resistant ovarian cancer now has treatment paths that improve overall survival, not only response or progression-free survival. Three biomarker results can alter selection.
62platinum-resistant HGSOC, ECOG 1several listed options
Narrow the field, or start from the front-runner?
Third lineplatinum-resistant HGSOCpreferred option off pathway
Trust the pathway, or test it?
68platinum-resistant, ECOG 2renal impairment, not trial-eligible
Trial exclusion: a verdict, or a prompt?
Platinum-resistant HGSOCdenial cites step therapygrade 2 neuropathy
Read the denial, or route around it?
62platinum-resistant HGSOCTier 4 coinsurance, limited means
Clinical gap first, or cost first?
What matters now
Platinum-resistant ovarian cancer now has treatment paths that improve overall survival, not only response or progression-free survival. Three biomarker results can alter selection.
5 Real World Scenarios
62platinum-resistant HGSOC, ECOG 1several listed options
Narrow the field, or start from the front-runner?
Where does the evidence land?
Third lineplatinum-resistant HGSOCpreferred option off pathway
Trust the pathway, or test it?
Where does the evidence land?
68platinum-resistant, ECOG 2renal impairment, not trial-eligible
Trial exclusion: a verdict, or a prompt?
Where does the evidence land?
Platinum-resistant HGSOCdenial cites step therapygrade 2 neuropathy
Read the denial, or route around it?
Where does the evidence land?
62platinum-resistant HGSOCTier 4 coinsurance, limited means
Clinical gap first, or cost first?
Where does the evidence land?